Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations

John SunyeczMenopauseRx, Inc., Hopwood, PA, USAAbstract: Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients’ mobility, independence, and survival. Care for incident fractures in this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	John Sunyecz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/70bc2989b0ba406f9d28e9a36ede7d2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:70bc2989b0ba406f9d28e9a36ede7d2b
record_format	dspace
spelling	oai:doaj.org-article:70bc2989b0ba406f9d28e9a36ede7d2b2021-12-02T07:28:51ZOptimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations1178-1998https://doaj.org/article/70bc2989b0ba406f9d28e9a36ede7d2b2008-12-01T00:00:00Zhttps://www.dovepress.com/optimizing-dosing-frequencies-for-bisphosphonates-in-the-management-of-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998John SunyeczMenopauseRx, Inc., Hopwood, PA, USAAbstract: Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients’ mobility, independence, and survival. Care for incident fractures in this age group must go beyond orthopedic repair, to assessment and treatment of the underlying bone fragility. Fracture risk can be reduced by vitamin D and calcium supplementation along with antiresorptive drug treatment. First-line osteoporosis pharmacotherapy employs nitrogen-containing bisphosphonates. The inconvenience of daily oral treatment has motivated development of weekly, monthly, and intermittent oral regimens, as well as quarterly and yearly intravenous (iv) regimens. Ibandronate is the first bisphosphonate to have shown direct anti-fracture efficacy with a non-daily regimen; it was approved for once-monthly oral dosing in 2005 and for quarterly iv dosing in 2006. Intermittent oral risedronate and yearly iv zoledronic acid were approved in 2007. Newly available regimens with extended dosing intervals reduce the inconvenience of bisphosphonate therapy and provide patients with a range of options from which to select a maximally sustainable course of treatment. This review discusses the development, efficacy, safety, and tolerability of extended-interval bisphosphonate regimens and examines their potential to improve patient acceptance and long-term success of osteoporosis treatment.Keywords: ibandronate, alendronate, risedronate, zoledronic acid, adherence, persistenceJohn SunyeczDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 611-627 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 John Sunyecz Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
description	John SunyeczMenopauseRx, Inc., Hopwood, PA, USAAbstract: Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients’ mobility, independence, and survival. Care for incident fractures in this age group must go beyond orthopedic repair, to assessment and treatment of the underlying bone fragility. Fracture risk can be reduced by vitamin D and calcium supplementation along with antiresorptive drug treatment. First-line osteoporosis pharmacotherapy employs nitrogen-containing bisphosphonates. The inconvenience of daily oral treatment has motivated development of weekly, monthly, and intermittent oral regimens, as well as quarterly and yearly intravenous (iv) regimens. Ibandronate is the first bisphosphonate to have shown direct anti-fracture efficacy with a non-daily regimen; it was approved for once-monthly oral dosing in 2005 and for quarterly iv dosing in 2006. Intermittent oral risedronate and yearly iv zoledronic acid were approved in 2007. Newly available regimens with extended dosing intervals reduce the inconvenience of bisphosphonate therapy and provide patients with a range of options from which to select a maximally sustainable course of treatment. This review discusses the development, efficacy, safety, and tolerability of extended-interval bisphosphonate regimens and examines their potential to improve patient acceptance and long-term success of osteoporosis treatment.Keywords: ibandronate, alendronate, risedronate, zoledronic acid, adherence, persistence
format	article
author	John Sunyecz
author_facet	John Sunyecz
author_sort	John Sunyecz
title	Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
title_short	Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
title_full	Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
title_fullStr	Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
title_full_unstemmed	Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
title_sort	optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/70bc2989b0ba406f9d28e9a36ede7d2b
work_keys_str_mv	AT johnsunyecz optimizingdosingfrequenciesforbisphosphonatesinthemanagementofpostmenopausalosteoporosispatientconsiderations
_version_	1718399407867559936

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations

Ejemplares similares